Aliskiren-induced QT interval prolongation

Southern Medical Journal

Volumn 102, Issue 4, 2009, Pages 411-412

  Peitz, Gregory J ^a   Malesker, Mark A ^b   Sojka, S George ^b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b NONE

Author keywords

Aliskiren; QT prolongation; Side effect

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMIODARONE; AMLODIPINE; CLONIDINE; FUROSEMIDE; INSULIN; METFORMIN; METOPROLOL; OLMESARTAN; POTASSIUM CHLORIDE; RENIN INHIBITOR; SERTRALINE; SOTALOL; WARFARIN;

AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE REGULATION; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HEART ARREST; HUMAN; HYPERTENSION; QT PROLONGATION; RESUSCITATION; TORSADE DES POINTES;

AGED; AMIDES; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; FEMALE; FUMARATES; HUMANS; LONG QT SYNDROME; SOTALOL;

EID: 67651171386     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31818fc03a     Document Type: Article

References (5)

1. Package Insert. Tekturna® (Aliskiren). East Hanover, NJ, Novartis Pharmaceuticals Corporation, 2007.
2. Ayalasomayajula S, Yeh CM, Vaidyanathan S, et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol 2008;48:799-811. (Pubitemid 351871965)
3. D'Aloia A, Faggiano P, Brentana A, et al. Sustained torsades de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease. Int J Cardiol 2005;105:337-339. (Pubitemid 41605088)
4. Link MS, Foote CB, Sloan SB, et al. Torsade de pointes and prolonged qt interval from surreptitious use of sotalol: use of drug levels in diagnosis. Chest 1997;112:556-557.
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.